AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20609003 — intervention group
Group type: EXPERIMENTAL
Intervention: VAAM ingestion (3000 mg/day)
Number of subjects: 24
Study 20609003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18726947 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of oral desmopressin
Number of subjects: 27
Study 18726947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17680819 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol
Number of subjects: 20
Study 17680819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15007359 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC (Double-Blind, Placebo-Controlled Food Challenge)
Number of subjects: 43
Study 15007359 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC
Number of subjects: 43
Study 15007359 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE immunoblotting
Number of subjects: 43
Study 11520009 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression (n=21)
Number of subjects: 40
Study 11520009 — intervention group
Group type: COMPARATOR
Intervention: Non-suppression (n=19)
Number of subjects: 40
Study 10192125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 per cent plus bicarbonate 8.4 per cent
Number of subjects: 60
Study 10192125 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2 per cent alone
Number of subjects: 60
Study 8739022 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 36,742 (600 mg single oral dose)
Number of subjects: 0
Study 8739022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2127791 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2a (6 million units thrice weekly for 1 month, followed by 3 million units for 3 months, and 1 million units maintenance therapy for 8 months)
Number of subjects: 60
Study 2127791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 2127791 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients' sera for antibody to hepatitis C virus
Number of subjects: 60
Study 6996123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 6996123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6996123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (for large ulcers)
Number of subjects: 0
Study 6996123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for large ulcers)
Number of subjects: 0
Study 31581898 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise for 8 weeks
Number of subjects: 34
Study 30629984 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled group (controlling difficulty for each block in a videogame task)
Number of subjects: 60
Study 30629984 — intervention group
Group type: COMPARATOR
Intervention: Yoked group (difficulty matched to a self-controlled counterpart)
Number of subjects: 60
Study 28062937 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 148
Study 25533997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (single dose)
Number of subjects: 62
Study 25533997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25311949 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐MAC® videolaryngoscope
Number of subjects: 141
Study 25311949 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath® videolaryngoscope
Number of subjects: 141
Study 25311949 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope® Cobalt videolaryngoscope
Number of subjects: 141
Study 25311949 — intervention group
Group type: COMPARATOR
Intervention: Classic Macintosh MAC 3 laryngoscope
Number of subjects: 141
Study 23289490 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social norms
Number of subjects: 0
Study 23289490 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social norms
Number of subjects: 0
Study 23289490 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms
Number of subjects: 0
Study 23289490 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norms
Number of subjects: 0
Study 21479856 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS with 0.12 μL/kg perfluorobutane microbubbles
Number of subjects: 157
Study 21479856 — intervention group
Group type: COMPARATOR
Intervention: US
Number of subjects: 157
Study 21479856 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS (all doses combined)
Number of subjects: 157
Study 18467147 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin infiltration with 20 ml of ropivacaine 0.75% (Gr R)
Number of subjects: 42
Study 18467147 — intervention group
Group type: COMPARATOR
Intervention: Skin infiltration with 20 ml of 0.9% saline solution (Gr P)
Number of subjects: 42
Study 16204359 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (1 mg/kg IV for three days)
Number of subjects: 50
Study 12704366 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 12704366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11113831 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (N = 145) with multivariate analyses to elaborate the PRAM
Number of subjects: 217
Study 11113831 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (N = 72)
Number of subjects: 217
Study 9761805 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide plus bilateral orchiectomy
Number of subjects: 1387
Study 9761805 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bilateral orchiectomy
Number of subjects: 1387
Study 7824566 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30% menthol solution
Number of subjects: 0
Study 7824566 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% menthol solution
Number of subjects: 0
Study 7824566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min and 5-min inter-stimulus intervals
Number of subjects: 0
Study 3401076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole nafate
Number of subjects: 903
Study 3401076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime sodium
Number of subjects: 903
Study 3401076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium
Number of subjects: 903
Study 3401076 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 903
Study 31484786 — intervention group
Group type: EXPERIMENTAL
Intervention: Home NIV initiation
Number of subjects: 67
Study 31484786 — intervention group
Group type: COMPARATOR
Intervention: In-hospital NIV initiation
Number of subjects: 67
Study 29743026 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed, integrated online and mobile phone behavioral intervention including a weight gain tracker, diet and physical activity goal-setting and self-monitoring tools.
Number of subjects: 1689
Study 29743026 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group with access to informational tools, event reminders, and a blogging feature.
Number of subjects: 1689
Study 27650032 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement using DSA tumor blush
Number of subjects: 46
Study 27650032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-rater agreement using DSA tumor blush
Number of subjects: 46
Study 26201312 — intervention group
Group type: EXPERIMENTAL
Intervention: VPZ 5 mg
Number of subjects: 732
Study 26201312 — intervention group
Group type: EXPERIMENTAL
Intervention: VPZ 10 mg
Number of subjects: 732
Study 26201312 — intervention group
Group type: EXPERIMENTAL
Intervention: VPZ 20 mg
Number of subjects: 732
Study 26201312 — intervention group
Group type: EXPERIMENTAL
Intervention: VPZ 40 mg
Number of subjects: 732
Study 26201312 — intervention group
Group type: COMPARATOR
Intervention: LPZ 30 mg
Number of subjects: 732
Study 24213913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-adherent therapy
Number of subjects: 984
Study 24213913 — intervention group
Group type: COMPARATOR
Intervention: Non-guideline-adherent therapy
Number of subjects: 984
Study 24213913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended combination of amoxicillin-gentamicin
Number of subjects: 984
Study 24213913 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended regimens for patients with a catheter
Number of subjects: 984
Study 24213913 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-adherent therapy for patients with a catheter
Number of subjects: 984
Study 21521375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1996
Study 21521375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1996
Study 19043984 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with allergens absorbed on calcium phosphate
Number of subjects: 28
Study 19043984 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with allergens absorbed on aluminium hydroxide
Number of subjects: 28
Study 19043984 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 28
Study 16575552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (1.0 mg DMT/kg body weight)
Number of subjects: 15
Study 16575552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15000367 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient backpropagation neural network (BPNN) using neck movement variables as input
Number of subjects: 115
Study 15000367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 115
Study 10743447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine in sodium bicarbonate 0.1 mmol litre‐1
Number of subjects: 10
Study 10743447 — intervention group
Group type: COMPARATOR
Intervention: 1% plain lidocaine
Number of subjects: 10
Study 8694325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 1 microgram/mL at thoracic level (Ts)
Number of subjects: 37
Study 8694325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 1 microgram/mL at lumbar level (Ls)
Number of subjects: 37
Study 8694325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 1 microgram/mL combined with bupivacaine 1 mg/mL at thoracic level (Tsb)
Number of subjects: 37
Study 8694325 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 37
Study 8694325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion (all groups)
Number of subjects: 37
Study 9343570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixel counting method
Number of subjects: 100
Study 9343570 — intervention group
Group type: COMPARATOR
Intervention: Tessellation method
Number of subjects: 100
Study 3130255 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycholate (DCA)
Number of subjects: 6
Study 3130255 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholate (CDCA)
Number of subjects: 6
Study 3130255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholate (UDCA)
Number of subjects: 6
Study 3130255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyodeoxycholate (HDCA)
Number of subjects: 6
Study 3130255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursocholate (UCA)
Number of subjects: 6
Study 3130255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholate (CA)
Number of subjects: 6
Study 30347735 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIN (continued exercise for 4 weeks)
Number of subjects: 22
Study 30347735 — intervention group
Group type: COMPARATOR
Intervention: DETRAIN (discontinued exercise)
Number of subjects: 22
Study 28482858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction group (33% and 50% dose reduction of biologics)
Number of subjects: 120
Study 28482858 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no dose reduction)
Number of subjects: 120
Study 28482858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction group
Number of subjects: 120
Study 28482858 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26185017 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diuretics
Number of subjects: 1213
Study 26185017 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ACE-inhibitors
Number of subjects: 1213
Study 26185017 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diuretics, insulin, and digitalis
Number of subjects: 1213
Study 26185017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diuretic and ACE-inhibitor
Number of subjects: 1213
Study 26185017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 1213
Study 23558157 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 100
Study 23558157 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily darunavir/ritonavir (DRV/r) 600/100 mg
Number of subjects: 100
Study 20854382 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20, 40 and 60 mg daily
Number of subjects: 203
Study 20854382 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 203
Study 20854382 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoalbuminuric group
Number of subjects: 203
Study 20854382 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuric group
Number of subjects: 203
Study 20854382 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuric group
Number of subjects: 203
Study 20854382 — intervention group
Group type: EXPERIMENTAL
Intervention: All diabetic groups (normo, micro, macroalbuminuric)
Number of subjects: 203
Study 18173400 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioresorbable PLA barrier device (Atrisorb) combined with autogenous bone grafting
Number of subjects: 40
Study 18173400 — intervention group
Group type: COMPARATOR
Intervention: Bone grafting solo (control)
Number of subjects: 40
Study 16982943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (62.5 mg for 1 day and 125 mg for the following 2 days)
Number of subjects: 20
Study 16982943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15339556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinobufacini injection
Number of subjects: 100
Study 15339556 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 10726719 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 2/Ind 0.625 mg
Number of subjects: 438
Study 10726719 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 4/Ind 1.25 mg
Number of subjects: 438
Study 10726719 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 8/Ind 2.5 mg
Number of subjects: 438
Study 10726719 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 0/Ind 1.25 mg
Number of subjects: 438
Study 10726719 — intervention group
Group type: EXPERIMENTAL
Intervention: Per 2/Ind 1.25 mg
Number of subjects: 438
Study 10726719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 10726719 — intervention group
Group type: EXPERIMENTAL
Intervention: Other doses (0-4.6%)
Number of subjects: 438
Study 8694206 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 8694206 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study 1485136 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (4 capsules/day)
Number of subjects: 120
Study 1485136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6585371 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline therapy for 2 weeks
Number of subjects: 9
Study 6585371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole therapy for 1 week
Number of subjects: 9
Study 6585371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined systemic antimicrobial therapy and mechanical plaque control
Number of subjects: 9
Study 31237183 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (1000 mg/day)
Number of subjects: 98
Study 31237183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 mg/day)
Number of subjects: 98
Study 29734387 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized T7 promoter variants
Number of subjects: 7847
Study 29734387 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro transcription/translation system
Number of subjects: 7847
Study 26960912 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention programme on the use of respiratory health status tools in primary care practices in Mallorca.
Number of subjects: 88194
Study 26960912 — intervention group
Group type: COMPARATOR
Intervention: Control practices in Ibiza and Menorca (non-intervention group).
Number of subjects: 88194
Study 26960912 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention programme on the use of respiratory health status tools.
Number of subjects: 88194
Study 24885938 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (hand instruments/high‐viscosity glass‐ionomer)
Number of subjects: 66
Study 24885938 — intervention group
Group type: COMPARATOR
Intervention: CRT/clinic (rotary instrumentation/resin composite)
Number of subjects: 66
Study 24885938 — intervention group
Group type: COMPARATOR
Intervention: CRT/GA (rotary instrumentation/resin composite under general anaesthesia)
Number of subjects: 66
Study 22716975 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine for 6 weeks (zidovudine-alone group)
Number of subjects: 1684
Study 22716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug group)
Number of subjects: 1684
Study 22716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group)
Number of subjects: 1684
Study 22716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall transmission rate
Number of subjects: 1684
Study 22716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug group
Number of subjects: 1684
Study 19798489 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye gaze cues
Number of subjects: 0
Study 19798489 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrow pointing distractors
Number of subjects: 0
Study 19798489 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical adults)
Number of subjects: 0
Study 17683996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clodronate (900 mg, n = 33)
Number of subjects: 67
Study 17683996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15621327 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional analysis technique
Number of subjects: 0
Study 11880863 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg p.o., fast release form)
Number of subjects: 45
Study 11880863 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 45
Study 11880863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10430963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical thrombolysis with urokinase
Number of subjects: 13
Study 10430963 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombolysis alone
Number of subjects: 13
Study 7598063 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate overfeeding (50% above energy requirements for 14 days)
Number of subjects: 16
Study 7598063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat overfeeding (50% above energy requirements for 14 days)
Number of subjects: 16
Study 2135695 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7000598 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide treatment in insulin dependent diabetics
Number of subjects: 736
Study 7000598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorpropamide treatment)
Number of subjects: 736
Study 7000598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin dependent diabetics
Number of subjects: 736
Study 7000598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin dependent diabetics with family history
Number of subjects: 736
Study 31968003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-performance routine interventions
Number of subjects: 54
Study 31968003 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 54
Study 31968003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative PPR use
Number of subjects: 54
Study 31968003 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated PPR use
Number of subjects: 54
Study 30982783 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong practice
Number of subjects: 93
Study 30982783 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 93
Study 30982783 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong practice + cognitive training
Number of subjects: 93
Study 27778171 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port cholecystectomy (SPC)
Number of subjects: 600
Study 27778171 — intervention group
Group type: COMPARATOR
Intervention: Multi-port cholecystectomy (MPC)
Number of subjects: 600
Study 25944518 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra-articular catheter (IAC)
Number of subjects: 120
Study 25944518 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 120
Study 23599979 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 1 f.Lg/L (group A)
Number of subjects: 120
Study 23599979 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 2 f.Lg/L (group B)
Number of subjects: 120
Study 23599979 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 3 f.Lg/L (group C)
Number of subjects: 120
Study 23599979 — intervention group
Group type: EXPERIMENTAL
Intervention: Target controlled infusion of remifentanil at 4 f.Lg/L (group D)
Number of subjects: 120